RxDoctor Payments Data

Lisa Saiman

Pediatric Infectious Diseases · New York, NYNPI 1306819404

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (48.5%), royalties or licence payments and travel and lodging — rather than concentrated in one kind of arrangement. Merck accounts for 85.5% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2023 at $40,693 and has fallen 97.7% since, to $935 in 2025. Among pediatric infectious diseases clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$73,241in general payments, 2019–2025

Across 50 payments — averaging $1464.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$63K
  • AstraZeneca$5K
  • Pfizer$4K
  • Seqirus USA Inc$1K
$890,330in research payments, 2019–2025

Across 25 payments — averaging $35,613 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Merck$890K
  • Regeneron$563

What the payments were for

  • Royalty or licence$33,48046%
  • Consulting fees$35,48948%
  • Speaking & faculty fees$1,0001%
  • Travel & lodging$2,4993%
  • Food & beverage$7731%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck39$62,587
AstraZeneca5$5,194
Pfizer3$4,335
Seqirus USA Inc3$1,125

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$73,241 in reported general payments places this provider in the 95th percentile of 73 pediatric infectious diseases providers in New York.

See all pediatric infectious diseases providers in New York →

Other pediatric infectious diseases in New York

See the full list for New York →

Where these figures come from

Is this you, or does something look wrong? →